A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of

See also
Status	Clinical Trial	Phase
Completed	`NCT03067155` - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.	Phase 2
Completed	`NCT02324244` - CMV Intensive Care Units	N/A
Enrolling by invitation	`NCT06263218` - Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
Recruiting	`NCT04934527` - Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection	Phase 2
Not yet recruiting	`NCT06075927` - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT	Phase 1/Phase 2
Not yet recruiting	`NCT06341686` - Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection	Phase 3
Recruiting	`NCT02136797` - Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Terminated	`NCT02843880` - Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study	N/A
Recruiting	`NCT04278547` - Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response	Phase 4
Recruiting	`NCT06021210` - Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS	Phase 2
Active, not recruiting	`NCT01633476` - CMV Modulation of the Immune System in ANCA-associated Vasculitis	Phase 2
Suspended	`NCT02988258` - Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT	Phase 1
Recruiting	`NCT03159364` - Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections	Phase 1/Phase 2
Recruiting	`NCT05089838` - CMV-TCR-T Cells for Refractory CMV Infection After HSCT	Phase 1
Enrolling by invitation	`NCT05656599` - Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Completed	`NCT02985775` - Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation	Phase 1/Phase 2
Recruiting	`NCT02083731` - MSC for Treatment of CMV Infection	Phase 2
Recruiting	`NCT02779439` - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation	Phase 1
Recruiting	`NCT03798301` - Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells	Phase 1
Completed	`NCT02550639` - Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant	Phase 4

NCT number	NCT04017962
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Genovefa Papanicolaou, MD
Phone	347-501-0044
Email	papanicg@mskcc.org
Status	Recruiting
Phase	Phase 2
Start date	July 19, 2019
Completion date	July 2024

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms